MS Drugs

In your organisation how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 12 months, calendar year of 2015 if possible?

Please provide the number of patients by treatment for the following disease modifying drugs:
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Ampyra (fampyra)
Peginterferon beta-1a (plegridy)
Others

Please find below the total number of patients under the care of Neurology who have been treated with the listed MS disease modifying drugs in the past 12 months. The Trust does not record the indication for treatment on the pharmacy dispensing system so the data may, therefore, include patients who have been treated with these drugs for other indications than those listed in the request.

Lemtrada (alemtuzumab) – 0
Rebif (beta interferon-1a) – 18
Extavia (beta interferon-1b) – 0
Tecfidera (dimethyl fumarate) – 20
Ampyra (fampyra) – 0
Gilenya (fingolimod) – 5
Copaxone (glatiramer acetate) – 17
Avonex (interferon beta-1a) – 6
Betaferon (interferon beta-1b) – 4
Tysabri (natalizumab) – 0
Peginterferon beta-1a (plegridy) – 0
Aubagio (teriflunomide) – 0

©2017 Royal Surrey County Hospital

Log in with your credentials

or    

Forgot your details?